One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

One month degarelix/comparator treatment for prostate cancer in Chinese population

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Goserelin

Criteria

Inclusion Criteria:

• Chinese male over 18 years

• Adenocarcinoma of the prostate

• Relevant disease status based on lab values and as judged by the physician

• Life expectancy of at least a year

Exclusion Criteria:

• Previous hormonal treatment for prostate cancer

• Considered to be candidate for curative therapy

• Risk or history of any serious or significant health condition

• Has received an investigational drug within the last 28 days and no previous treatment with degarelix